SGMO - Sangamo Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Brisbane,
United States
Type: Equity
SGMO price evolution
SGMO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $27.79 | $55.33 | $46.7 | |
| Short term investments | $35.8 | |||
| Net receivables | $10.5 | $0.58 | $0.69 | $0.92 |
| Inventory | ||||
| Total current assets | $58.13 | $40.08 | $68.64 | $94.33 |
| Long term investments | ||||
| Property, plant & equipment | $36.91 | $39.29 | $42.95 | $52.87 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $52.94 | $60.33 | $70.99 | |
| Total investments | $35.8 | |||
| Total assets | $111.26 | $93.01 | $128.96 | $165.32 |
| Current liabilities | ||||
| Accounts payable | $19.79 | $17.59 | $15.47 | $15.26 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $43.16 | $39.01 | $40.24 | $47.73 |
| Long term debt | $29.1 | $30.82 | $33.52 | |
| Total noncurrent liabilities | $30.32 | $32.02 | $34.7 | |
| Total debt | $29.1 | $30.82 | $33.52 | |
| Total liabilities | $72.13 | $69.32 | $72.26 | $82.43 |
| Shareholders' equity | ||||
| Retained earnings | -$1480.92 | -$1491.59 | -$1455.46 | -$1406.38 |
| Other shareholder equity | -$4.22 | -$5.88 | -$5.8 | -$4.59 |
| Total shareholder equity | $23.69 | $56.7 | $82.89 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $46.7 | $101.94 | $180.37 | $132.83 |
| Short term investments | $35.8 | $177.19 | $197.68 | $510.09 |
| Net receivables | $0.92 | $4.47 | $6.01 | $5.22 |
| Inventory | ||||
| Total current assets | $94.33 | $300.33 | $398.77 | $659.67 |
| Long term investments | $29.84 | $88.17 | $50.53 | |
| Property, plant & equipment | $52.87 | $125.53 | $124.7 | $112.37 |
| Goodwill & intangible assets | $88.28 | $93.46 | $100.93 | |
| Total noncurrent assets | $70.99 | $262.18 | $323.15 | $278.88 |
| Total investments | $35.8 | $207.03 | $285.85 | $560.62 |
| Total assets | $165.32 | $562.51 | $721.92 | $938.55 |
| Current liabilities | ||||
| Accounts payable | $15.26 | $22.42 | $9.76 | $12.55 |
| Deferred revenue | $161.16 | $252.49 | $336.69 | |
| Short long term debt | ||||
| Total current liabilities | $47.73 | $111.71 | $127.89 | $143.55 |
| Long term debt | $33.52 | $38.99 | $44.05 | $38.4 |
| Total noncurrent liabilities | $34.7 | $155.84 | $218.69 | $297.64 |
| Total debt | $33.52 | $38.99 | $44.05 | $38.4 |
| Total liabilities | $82.43 | $267.55 | $346.58 | $441.18 |
| Shareholders' equity | ||||
| Retained earnings | -$1406.38 | -$1148.55 | -$956.27 | -$777.98 |
| Other shareholder equity | -$4.59 | -$8.4 | -$3.99 | $5.42 |
| Total shareholder equity | $82.89 | $294.96 | $375.34 | $498.23 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $49.41 | $0.36 | $0.48 | $2.04 |
| Cost of revenue | ||||
| Gross Profit | $0.36 | $0.48 | $2.04 | |
| Operating activities | ||||
| Research & development | $24.22 | $35.89 | $50.71 | |
| Selling, general & administrative | $12.04 | $11.77 | $13.1 | |
| Total operating expenses | $38.78 | $37.44 | $52.01 | $64.1 |
| Operating income | -$37.08 | -$51.53 | -$62.06 | |
| Income from continuing operations | ||||
| EBIT | -$36.05 | -$48.99 | -$60.57 | |
| Income tax expense | $0.09 | $0.07 | $0.1 | -$0.27 |
| Interest expense | $0.13 | |||
| Net income | ||||
| Net income | $9.38 | -$36.13 | -$49.09 | -$60.3 |
| Income (for common shares) | -$36.13 | -$49.09 | -$60.3 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $176.23 | $111.3 | $110.7 | $118.19 |
| Cost of revenue | ||||
| Gross Profit | $176.23 | $111.3 | $110.7 | $118.19 |
| Operating activities | ||||
| Research & development | $234.06 | $249.9 | $230.82 | $180.65 |
| Selling, general & administrative | $61.17 | $62.68 | $63.22 | $67.1 |
| Total operating expenses | $450.24 | $312.58 | $294.04 | $247.74 |
| Operating income | -$274 | -$201.28 | -$183.34 | -$129.55 |
| Income from continuing operations | ||||
| EBIT | -$262.9 | -$191.85 | -$177.98 | -$120.65 |
| Income tax expense | -$5.07 | $0.43 | $0.31 | $0.34 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$257.83 | -$192.28 | -$178.29 | -$121 |
| Income (for common shares) | -$257.83 | -$192.28 | -$178.29 | -$121 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$36.13 | -$49.09 | -$60.3 | |
| Operating activities | ||||
| Depreciation | $2.57 | $2.53 | $3.01 | |
| Business acquisitions & disposals | $0.13 | |||
| Stock-based compensation | $3.06 | $2.72 | $6.11 | |
| Total cash flows from operations | -$26.88 | -$48.66 | -$50.54 | |
| Investing activities | ||||
| Capital expenditures | -$2.67 | |||
| Investments | $35.84 | $40.38 | ||
| Total cash flows from investing | $36.2 | $0.13 | $35.84 | $37.71 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | -$0.45 | $22.52 | $0.22 | |
| Net borrowings | ||||
| Total cash flows from financing | $21.39 | -$0.53 | $22.12 | $0.17 |
| Effect of exchange rate | $0.2 | -$0.26 | -$0.67 | $1.35 |
| Change in cash and equivalents | -$6 | -$27.55 | $8.63 | -$11.31 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$257.83 | -$192.28 | -$178.29 | -$121 |
| Operating activities | ||||
| Depreciation | $22.19 | $20.56 | $17.64 | $13.37 |
| Business acquisitions & disposals | -$0.12 | -$0.7 | ||
| Stock-based compensation | $27.36 | $31.65 | $32.96 | $25.71 |
| Total cash flows from operations | -$224.84 | -$223.63 | -$233.25 | $169.88 |
| Investing activities | ||||
| Capital expenditures | -$21.16 | -$20.17 | -$23.28 | -$14.71 |
| Investments | $174.69 | $79.46 | $271.6 | -$256.21 |
| Total cash flows from investing | $153.53 | $59.28 | $248.2 | -$271.63 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.04 | $86.76 | $36.12 | $153.87 |
| Net borrowings | ||||
| Total cash flows from financing | $14.59 | $84.66 | $32.86 | $153.1 |
| Effect of exchange rate | $1.48 | $1.25 | -$0.26 | -$0.45 |
| Change in cash and equivalents | -$55.24 | -$78.43 | $47.54 | $50.9 |
News
Fundamentals
| Market cap | $150.21M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 208.62M |
| Revenue | $52.29M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$136.13M |
| Revenue Q/Q | 425.77% |
| Revenue Y/Y | -74.04% |
| P/E ratio | -1.10 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 2.87 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$0.65 |
|---|---|
| ROA | -109.22% |
| ROE | N/A |
| Debt/Equity | 0.99 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.35 |
| Quick ratio | N/A |